News | Page 29 | Graduate School of Medical Sciences

Du Vigneaud Abstract Submission NOW OPEN

Abstract submission for the 36th Annual Vincent du Vigneaud Student Research Symposiumis NOW OPEN, and will continue through February 29, 2016. This year's Du Vigneaud Symposium will take place on Thursday, April 21, 2016.

Please submit abstracts by using the Du Vigneaud Abstract Submission Form. Please note that if you plan to give a talk you should submit your abstract early! Talk priority will be given to older students and to students who submit early. We look forward to...

A Special Symposium in Honor of Dr. Carl Nathan

Infection, Inflammation and Immunity:Fifty Years of Lessons from Interferon-gammaA Special Symposium in Honor of Dr. Carl NathanHosted by
Laurie H. Glimcher, MD

Stephen and Suzanne Weiss Dean, Weill Cornell Medicine (WCM)

Gary A. Koretzky, MD, PhD

Dean, Weill Cornell Graduate School & Vice Dean for Research (WCM)

Tuesday, April 19, 2016 1:00-5:00pmBelfer Research Building, Room 302A-D, 413 E. 69th St., NY, NY 10021
...

NY Graduate Student Cell Biology Symposium

NY Graduate Student Symposium on Cell Biology

SPOTTED!

Don't forget to submit your abstracts for the NY Graduate Student Symposium on Cell Biology! Deadline is Monday, February 15th.

**Submission includes ALL STUDENTS who work in cancer biology, cell biology, and all other related fields!

Registration is March 1, 2016. Click here to register

Fast talkers, quick thinkers

The winners from the inaugural Three Minute Thesis (3MT®) competition at Weill Cornell Graduate School were featured in the latest edition of Weill Cornell Medicine magazine.

Click here to read the article (page 48)

Weill Cornell's Cantley wins Wolf Prize in Medicine

Considered “Israel’s Nobel Prize,” Wolf Prizes are given annually to scientists and researchers who have made seminal achievements in their fields. This year, seven winners in five categories – agriculture, the arts, chemistry, medicine and physics – will divide a $500,000 cash prize.

Cantley was recognized for his discovery of an enzyme called phosphoinositide 3-kinase (PI3K) and the signaling pathway that it controls. Cantley found that human cancers frequently occur due to...

Weill Cornell PhD candidates featured in 2016 Forbes Edition "30 Under 30: Healthcare"

Weill Cornell Medicine doctoral candidates Kaitlyn Gayvert and Neel Madhukar have been recognized as part of Forbes magazine's "30 Under 30" list, which lauds the successes of young change agents in 20 professional fields.

Gayvert and Madhukar, both enrolled in the computational biology and medicine program at Weill Cornell Medicine, were named as two of the most emerging talents younger than 30 in healthcare nationwide. Forbes honored them for using big data algorithms to discover new...

Weill Cornell Biotech Club (WCBC) networking

WCBC Networking Event

The Weill Cornell Biotech Club hosted the NYC Graduate Biotech Consortium Networking event last week. Along with NYU, Sinai, and Hunter Biotech, the evening encouraged mingling and lively conversation with attendees from 5 difference schools in the New York City area, including attendance from some industry professionals.

Be sure to check out the Weill Cornell Biotech club's website for future events.

Protein Signaling Networks Act as Biomarker for Chemotherapy Sensitivity in Acute Myeloid Leukemia

An experimental chemotherapy kills leukemia cells that are abundant in proteins critical to cancer growth, according to new research from Weill Cornell Medicine. The findings may offer scientists a new biomarker to discern which patients with an aggressive form of the blood cancer will — or will not — respond to the treatment.

In the study, published Nov. 25 in Cell Reports, the investigators focused on a drug developed by Dr. Gabriela Chiosis at Memorial Sloan Kettering...

Biopsy tumor cells from a patient enrolled in the EXaCT-1 pilot program

New Treatment Options for Advanced-Stage Cancer Patients Revealed Through Next-Generation Sequencing Test

Weill Cornell Medicine recently received approval for EXaCT-1 by the New York State Department of Health. The test was developed by the institutions' precision medicine team. In May, the team published findings on its first 97 patients who underwent the test and found that scanning a patient's tumor to look for any genomic mutations — rather than limiting the screen to mutations commonly associated with a given patient's tumor type — worked. In 92 percent of cases in the pilot program, the...

Tumor Exosome Protein Signatures Predict Future Organ Sites of Cancer Spread

It's been a longstanding mystery — why certain types of cancers spread to particular organs in the body. Now, investigators from Weill Cornell Medicine have discovered precisely how this happens, supporting a century-old hypothesis known as the seed and soil theory of metastasis.

The culprit? Protein signatures on the membranes of small, tumor-secreted packages containing the blueprint that drives cancers to distant organs. These signatures could offer doctors a powerful new way...